EGFR+ Lung Cancer patient outcomes with early dose reduction of osimertinib

EGFR Positive UK shared a post on X about a recent paper by Marion Ferreira et al. published in Anti-Cancer Drugs, commenting:

“New study suggests that early dose reduction of osimertinib can improve advanced EGFR and Lung Cancer patient outcomes by managing toxicity without compromising the treatment’s efficacy.”

“Early dose reduction of osimertinib in advanced EGFR-mutated non-small cell lung cancer”

Authors: Mariona Ferreira, Matthew Ebia, Karen Reckamp

Source: EGFR Positive UK/X